Vico Therapeutics, a Leiden, Netherlands-based biotech company, has named Rupert Sandbrink, MD, PhD as its new chief medical officer, and Anders Hinsby, PhD as its new independent director, it was reported on Thursday.

Dr Sandbrink has more than twenty years of experience covering all stages of clinical development, from first-in-human studies to product launches. Most recently, he was the chief development & chief medical officer, at Topas Therapeutics GmbH. He has also served as executive vice president, Multiple Sclerosis/Neurology and Immunology at Forward Pharma A/S, and a member of Forward's Executive Management Team. He was vice president, head Experimental Medicine Women's Health & Common Mechanism Research at Bayer, and served as vice president, head Global Clinical Development Neurology, Ophthalmology, Haematology, Immunology.

Dr Hinsby has over 15 years of experience as a biotech entrepreneur, executive and investor. Presently, he is the CEO of Muna Therapeutics and served as entrepreneur-in-residence with Novo Seeds. He co-founded and was the CEO of Orphazyme A/S and led the firm's journey from University spin-out to a late-stage biopharmaceuticals company with a focus on rare diseases.